ScreenerHero

LPCN Lipocine Inc.

NAS · US · Healthcare · Biotechnology · lipocine.com
1.930USD-12.27%Mkt Cap: 15.91M $P/E: —

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone repl…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap15.91M USD
Enterprise Value-5.70M USD
Revenue (TTM)1.57M USD
Gross Profit-6.61M USD
Net Income (TTM)-9.63M USD
Revenue/Share0.24 USD
Last Price1.930 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.69
PEG—
EV/EBITDA0.46
EV/Revenue-3.63
P/S11.03
P/B0.80
EPS (TTM)-1.85
EPS (Forward)-1.24
52W Range
1.8101% of range12.37
52W High12.37 USD
52W Low1.810 USD
Profitability
Gross Margin-334.26%
Oper. Margin-1495.14%
EBITDA Margin0.00%
Profit Margin-487.06%
ROE-66.50%
ROA-56.61%
Growth
Revenue Growth-69.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.76M USD
CapEx (TTM)—
FCF Margin-442.18%
FCF Yield-43.62%
Net Debt-23.01M USD
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity1.18
Current Ratio11.48
Quick Ratio11.39
Book Value/Sh2.64 USD
Cash/Share2.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:17
Split DateMay 12, 2023
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+159.1%
Target Range4.000 USD – 6.000 USD
4.000+159.1% to mean6.000
# Analysts2
Ownership
Shares Out.8.24M
Float6.51M
Insiders4.96%
Institutions36.19%
Short Interest
Short Ratio3.5d
Short % Float1.23%
Short % Out.1.21%
Shares Short99.44K
Short (prev mo.)94.43K
Technical
SMA 502.160 (-10.6%)
SMA 2004.399 (-56.1%)
Beta0.40
S&P 52W Chg16.45%
Avg Vol (30d)3.61M
Avg Vol (10d)44.06K
Technical Indicators
RSI (14)37.0
MACD-0.0392
MACD Signal-0.0257
MACD Hist.-0.0135
BB Upper2.321 USD
BB Middle2.148 USD
BB Lower1.976 USD
BB Width16.08%
ATR (14)0.1838 USD
Vol Ratio (20d)0.43x